48 related articles for article (PubMed ID: 9044025)
1. High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms.
Hengzhuang W; Ciofu O; Yang L; Wu H; Song Z; Oliver A; Høiby N
Antimicrob Agents Chemother; 2013 Jan; 57(1):196-204. PubMed ID: 23089750
[TBL] [Abstract][Full Text] [Related]
2. Past and Present Perspectives on β-Lactamases.
Bush K
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061284
[TBL] [Abstract][Full Text] [Related]
3. Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
Kotsakis SD; Papagiannitsis CC; Tzelepi E; Tzouvelekis LS; Miriagou V
Antimicrob Agents Chemother; 2009 Aug; 53(8):3520-3. PubMed ID: 19470510
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Drug-Protein Interactions in the Bacterial Periplasm by Solution Nuclear Magnetic Resonance Spectroscopy.
Razew A; Herail Q; Miyachiro M; Anoyatis-Pelé C; Bougault C; Dessen A; Arthur M; Simorre JP
J Am Chem Soc; 2024 Apr; 146(13):9252-9260. PubMed ID: 38500259
[TBL] [Abstract][Full Text] [Related]
5. RAISE: a simple and novel method of generating random insertion and deletion mutations.
Fujii R; Kitaoka M; Hayashi K
Nucleic Acids Res; 2006; 34(4):e30. PubMed ID: 16493137
[TBL] [Abstract][Full Text] [Related]
6. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.
Sader HS; Gales AC
Drugs; 2001; 61(5):553-64. PubMed ID: 11368281
[TBL] [Abstract][Full Text] [Related]
7. Defining an extended-spectrum beta-lactamase.
Livermore DM
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():3-10. PubMed ID: 18154524
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase.
Matsumura N; Minami S; Mitsuhashi S
J Antimicrob Chemother; 1997 Jan; 39(1):31-4. PubMed ID: 9044025
[TBL] [Abstract][Full Text] [Related]
10. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
Medeiros AA; Hare R; Papa E; Adam C; Miller GH
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
[TBL] [Abstract][Full Text] [Related]
11. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
Babini GS; Yuan M; Livermore DM
Antimicrob Agents Chemother; 1998 May; 42(5):1168-75. PubMed ID: 9593145
[TBL] [Abstract][Full Text] [Related]
12. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem LJC10,627.
Yoshida M; Mitsuhashi S
Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):625-9. PubMed ID: 2209630
[TBL] [Abstract][Full Text] [Related]
13. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
[TBL] [Abstract][Full Text] [Related]
14. Hydrolytic rate at low drug concentration as a limiting factor in resistance to newer cephalosporins.
Hiraoka M; Inoue M; Mitsuhashi S
Rev Infect Dis; 1988; 10(4):746-51. PubMed ID: 3055173
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
